RAS family variants—most of which involve KRAS—are the most commonly occurring
hotspot mutations in human cancers and are associated with a poor prognosis. For almost …

Although RAS was formerly considered undruggable, various agents that inhibit RAS or
specific RAS oncoproteins have now been developed. Indeed, the importance of directly …

Abstract KRAS G12C mutation is prevalent in~ 4% of colorectal cancer (CRC) and is
associated with poor prognosis. Divarasib, a KRAS G12C inhibitor, has shown modest …

The current third-line (and beyond) treatment options for RAS-mutant metastatic colorectal
cancer have yielded limited efficacy. At the time of study start, the combination of sotorasib, a …

Over the past decade, RAS oncogenic proteins have transitioned from being deemed
undruggable to having two clinically approved drugs, with several more in advanced stages …

The Kirsten rat sarcoma viral oncogene homologue KRAS is among the most commonly
mutated oncogenes in human cancers, thus representing an attractive target for precision …

Cytokines are critical in regulating immune responses and cellular behavior, playing dual
roles in both normal physiology and the pathology of diseases such as cancer. These …

The integration of cancer biomarkers into oncology has revolutionized cancer treatment,
yielding remarkable advancements in cancer therapeutics and the prognosis of cancer …

Adagrasib, an irreversible, selective KRASG12C inhibitor, may be an effective treatment in
KRAS G12C-mutated colorectal cancer, particularly when combined with an anti-EGFR …

Metastatic colorectal cancer remains a deadly malignancy and is the third leading cause of
cancer-related death. The mainstay of treatment for metastatic colorectal cancer is …